A Retrospective Analysis of ADAMTS13 Enzymatic Activity Results in a Population With Thrombotic Thrombocytopenic Purpura Disease in the Arabian Gulf and Colombia (APOLO Study)

Little is known about the thrombospondin type-1 motif, member 13 (ADAMTS-13) enzymatic activity in subjects with suspected/confirmed thrombotic thrombocytopenic purpura (TTP) in the Arabian Gulf and Colombia. The retrospective analysis of ADAMTS13 enzymatic activity results in a population with thrombotic thrombocytopenic purpura disease in the Arabian Gulf and Colombia (APOLO study) aimed to report on ADAMTS-13 enzymatic activity, subject demographics, and the turnaround time for results. This study used laboratory analyses of ADAMTS-13 enzymatic activity in blood samples from subjects with suspected/confirmed TTP in the Arabian Gulf (N=235) and in Colombia (N=155). The primary objective was to report ADAMTS-13 enzymatic activity levels and distribution in categories: severe deficiency <10% (TTP diagnosis), borderline activity 10-20%, and no deficiency >20%. Descriptive statistics were performed using SAS 9.4 (SAS Institute Inc., North Carolina, USA). Among the 390 samples, the average ADAMTS-13 activity level was 42.8%±31.1. Severe deficiency (ADAMTS-13 activity <10%, 1.7%±1.9, indicative of TTP) was found in 91 samples (23.3%) and borderline ADAMTS-13 activity (15.4%±3.0) in 17 (4.4%) samples. The median age among subjects with TTP was 39 years. The average turnaround time for results was 4.4±5.9 days, with a median of 2.0 days. The average turnaround time was significantly longer for samples from the Arabian Gulf (6.5±6.9 days) compared to those from Colombia (1.2±0.8 days, Wilcoxon/Mann-Whitney W-value=18507.5, P<0.001). In conclusion, the median age of subjects with TTP in this study matched the age reported in the literature. The turnaround time is a global concern, as it can lead to delayed confirmatory results and potentially life-saving treatment. In Colombia, the turnaround time considerably benefits TTP management, underscoring the necessity to determine reasons behind occasional result turnaround delays in the Arabian Gulf.

Authors

Institutions

Publication Details

Journal
Cureus
Published
2026-02-18
DOI
https://doi.org/10.7759/cureus.103823
Primary Topic
Complement system in diseases
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A Retrospective Analysis of ADAMTS13 Enzymatic Activity Results in a Population With Thrombotic Thrombocytopenic Purpura Disease in the Arabian Gulf and Colombia (APOLO Study)

Yahia Aktham, Mohamed Zahir Chouikrat, S. Edris, Ahmed Mekky et al.
Cureus
Complement system in diseases
article

A Retrospective Analysis of ADAMTS13 Enzymatic Activity Results in a Population With Thrombotic Thrombocytopenic Purpura Disease in the Arabian Gulf and Colombia (APOLO Study)

Yahia Aktham, Mohamed Zahir Chouikrat, S. Edris, Ahmed Mekky, Mahmoud Younis, Hadia B Al Mahdi, Maria F Vargas, María A Cortés, Monica Fahmy
article en

Abstract

Little is known about the thrombospondin type-1 motif, member 13 (ADAMTS-13) enzymatic activity in subjects with suspected/confirmed thrombotic thrombocytopenic purpura (TTP) in the Arabian Gulf and Colombia. The retrospective analysis of ADAMTS13 enzymatic activity results in a population with thrombotic thrombocytopenic purpura disease in the Arabian Gulf and Colombia (APOLO study) aimed to report on ADAMTS-13 enzymatic activity, subject demographics, and the turnaround time for results. This study used laboratory analyses of ADAMTS-13 enzymatic activity in blood samples from subjects with suspected/confirmed TTP in the Arabian Gulf (N=235) and in Colombia (N=155). The primary objective was to report ADAMTS-13 enzymatic activity levels and distribution in categories: severe deficiency <10% (TTP diagnosis), borderline activity 10-20%, and no deficiency >20%. Descriptive statistics were performed using SAS 9.4 (SAS Institute Inc., North Carolina, USA). Among the 390 samples, the average ADAMTS-13 activity level was 42.8%±31.1. Severe deficiency (ADAMTS-13 activity <10%, 1.7%±1.9, indicative of TTP) was found in 91 samples (23.3%) and borderline ADAMTS-13 activity (15.4%±3.0) in 17 (4.4%) samples. The median age among subjects with TTP was 39 years. The average turnaround time for results was 4.4±5.9 days, with a median of 2.0 days. The average turnaround time was significantly longer for samples from the Arabian Gulf (6.5±6.9 days) compared to those from Colombia (1.2±0.8 days, Wilcoxon/Mann-Whitney W-value=18507.5, P<0.001). In conclusion, the median age of subjects with TTP in this study matched the age reported in the literature. The turnaround time is a global concern, as it can lead to delayed confirmatory results and potentially life-saving treatment. In Colombia, the turnaround time considerably benefits TTP management, underscoring the necessity to determine reasons behind occasional result turnaround delays in the Arabian Gulf.

CureusVol. 18(2)
Ain Shams University (EG), King Abdulaziz University (SA), Sanofi (France) (FR), SNUH SMG-SNU Boramae Medical Center (KR), Asociación Colombiana de Facultades de Ingeniería (CO)
Sanofi
Life below water
Openalex Percentile: Top 49%
Complement system in diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.